These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 27104089)

  • 1. Systems Pharmacology Approach for Prediction of Pulmonary and Systemic Pharmacokinetics and Receptor Occupancy of Inhaled Drugs.
    Boger E; Evans N; Chappell M; Lundqvist A; Ewing P; Wigenborg A; Fridén M
    CPT Pharmacometrics Syst Pharmacol; 2016 Apr; 5(4):201-10. PubMed ID: 27104089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Systematic Analysis of the Sensitivity of Plasma Pharmacokinetics to Detect Differences in the Pulmonary Performance of Inhaled Fluticasone Propionate Products Using a Model-Based Simulation Approach.
    Weber B; Hochhaus G
    AAPS J; 2015 Jul; 17(4):999-1010. PubMed ID: 25933600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting Pulmonary Pharmacokinetics from In Vitro Properties of Dry Powder Inhalers.
    Bhagwat S; Schilling U; Chen MJ; Wei X; Delvadia R; Absar M; Saluja B; Hochhaus G
    Pharm Res; 2017 Dec; 34(12):2541-2556. PubMed ID: 28799097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A mechanistic framework for a priori pharmacokinetic predictions of orally inhaled drugs.
    Hartung N; Borghardt JM
    PLoS Comput Biol; 2020 Dec; 16(12):e1008466. PubMed ID: 33320846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of particle deposition density of dry powders on the results produced by an in vitro test system simulating dissolution- and absorption rates in the lungs.
    Malmlöf M; Nowenwik M; Meelich K; Rådberg I; Selg E; Burns J; Mascher H; Gerde P
    Eur J Pharm Biopharm; 2019 Jun; 139():213-223. PubMed ID: 30862480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic profile analyses for inhaled drugs in humans using the lung delivery and disposition model.
    Raut A; Dhapare S; Venitz J; Sakagami M
    Biopharm Drug Dispos; 2020 Feb; 41(1-2):32-43. PubMed ID: 31691979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Revealing the Regional Localization and Differential Lung Retention of Inhaled Compounds by Mass Spectrometry Imaging.
    Hamm GR; Bäckström E; Brülls M; Nilsson A; Strittmatter N; Andrén PE; Grime K; Fridén M; Goodwin RJA
    J Aerosol Med Pulm Drug Deliv; 2020 Feb; 33(1):43-53. PubMed ID: 31364961
    [No Abstract]   [Full Text] [Related]  

  • 8. Predicting Exposure After Oral Inhalation of the Selective Glucocorticoid Receptor Modulator, AZD5423, Based on Dose, Deposition Pattern, and Mechanistic Modeling of Pulmonary Disposition.
    Bäckman P; Tehler U; Olsson B
    J Aerosol Med Pulm Drug Deliv; 2017 Apr; 30(2):108-117. PubMed ID: 27740878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of functional respiratory imaging to characterize the effect of inhalation profile and particle size on lung deposition of inhaled corticosteroid/long-acting β2-agonists delivered via a pressurized metered-dose inhaler.
    Van Holsbeke C; De Backer J; Vos W; Marshall J
    Ther Adv Respir Dis; 2018; 12():1753466618760948. PubMed ID: 29499614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of a One-Dimensional Computational Model for the Prediction of Deposition from a Dry Powder Inhaler.
    Gourgoulianis K; Daniil Z; Athanasiou K; Rozou S; Bontozoglou V
    J Aerosol Med Pulm Drug Deliv; 2017 Dec; 30(6):435-443. PubMed ID: 28683222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translational model to predict pulmonary pharmacokinetics and efficacy in man for inhaled bronchodilators.
    Hendrickx R; Lamm Bergström E; Janzén DLI; Fridén M; Eriksson U; Grime K; Ferguson D
    CPT Pharmacometrics Syst Pharmacol; 2018 Mar; 7(3):147-157. PubMed ID: 29280349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pulmonary deposition of fluticasone propionate/formoterol in healthy volunteers, asthmatics and COPD patients with a novel breath-triggered inhaler.
    Kappeler D; Sommerer K; Kietzig C; Huber B; Woodward J; Lomax M; Dalvi P
    Respir Med; 2018 May; 138():107-114. PubMed ID: 29724381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids.
    Hübner M; Hochhaus G; Derendorf H
    Immunol Allergy Clin North Am; 2005 Aug; 25(3):469-88. PubMed ID: 16054538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary targeting of sustained release formulation of budesonide in neonatal rats.
    Arya V; Coowanitwong I; Brugos B; Kim WS; Singh R; Hochhaus G
    J Drug Target; 2006 Dec; 14(10):680-6. PubMed ID: 17162737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new methodology for predicting human pharmacokinetics for inhaled drugs from oratracheal pharmacokinetic data in rats.
    Jones RM; Harrison A
    Xenobiotica; 2012 Jan; 42(1):75-85. PubMed ID: 22077102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lung deposition and systemic availability of fluticasone Diskus and budesonide Turbuhaler in children.
    Agertoft L; Pedersen S
    Am J Respir Crit Care Med; 2003 Oct; 168(7):779-82. PubMed ID: 12893646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel in vivo receptor occupancy methodology for the glucocorticoid receptor: toward an improved understanding of lung pharmacokinetic/pharmacodynamic relationships.
    Boger E; Ewing P; Eriksson UG; Fihn BM; Chappell M; Evans N; Fridén M
    J Pharmacol Exp Ther; 2015 May; 353(2):279-87. PubMed ID: 25680710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary Dissolution of Poorly Soluble Compounds Studied in an ex Vivo Rat Lung Model.
    Eriksson J; Thörn H; Sjögren E; Holmstén L; Rubin K; Lennernäs H
    Mol Pharm; 2019 Jul; 16(7):3053-3064. PubMed ID: 31136181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, dose-ranging study of a fluticasone propionate multidose dry powder inhaler in adolescents and adults with uncontrolled asthma not previously treated with inhaled corticosteroids.
    Kerwin EM; Gillespie M; Song S; Steinfeld J
    J Asthma; 2017 Jan; 54(1):89-98. PubMed ID: 27285965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.